Comments on: Biotech chameleons: Quark Pharma aims for $81M IPO

By: Quark Pharma update: Not quite such a chameleon, after all » VentureBeat

Quark Pharma update: Not quite such a chameleon, after all » VentureBeat — Mon, 18 Feb 2008 23:35:30 +0000

[...] gene-silencing technology called RNA interference, or RNAi. At the time, I labeled the company a biotech chameleon — a term I used to describe biotechs that reinvent themselves, often abruptly and without [...]

By: VentureBeat » RNA-drug developer Quark aims for $30M following failed IPO

VentureBeat » RNA-drug developer Quark aims for $30M following failed IPO — Mon, 28 Jan 2008 22:26:56 +0000

[...] hopes to raise $30 million in an eighth funding round, VentureWire reports. Last year, Quark sought $80.5 million in an ultimately abortive [...]

By: VentureBeat » Quark Pharma IPO delayed

VentureBeat » Quark Pharma IPO delayed — Fri, 10 Aug 2007 23:49:13 +0000

[...] Pharmaceuticals, the biotech chameleon I profiled here, delayed an IPO that the company expects to raise as much as $81 million, VentureWire reports [...]

By: max

max — Fri, 27 Jul 2007 11:17:39 +0000

nice to be where?

By: Chizoba Okeke

Chizoba Okeke — Fri, 08 Jun 2007 00:00:14 +0000

Nice to be here!